AICAR Research & Listing Availability
Current AICAR vial offers are unavailable in this comparison. Research information remains available; this does not establish permanent discontinuation.
Current AICAR vial offers are unavailable in this comparison. Research information remains available; this does not establish permanent discontinuation.
About AICAR
InvestigationalAlso known as: AICA Ribonucleotide · 5-Aminoimidazole-4-carboxamide ribonucleotide · Acadesine · ZMP precursorAICAR is a small-molecule AMPK activator (a nucleotide analogue) studied in metabolic and exercise-physiology research. It is a chemical compound, not a peptide, so the certificate of analysis (COA) is about chemical purity and identity rather than a sequence.
What to check before you buy AICAR:
- A third-party COA showing ≥98% purity by HPLC, with identity confirmed by mass spec (and ideally NMR) — AICAR is a small molecule, so you're checking chemical purity, not a peptide sequence.
- A COA dated within the last 6–12 months tied to the exact batch you are buying.
- The actual amount per vial matching the label. Under- or over-filled vials are the common failure mode and make your dose math unreliable.
AICAR was originally developed as a cardioprotective and anti-leukemic drug (acadesine) and reached Phase 3 in chronic lymphocytic leukemia (the BENDA-Acadesine program), where it did not advance.[4] Its post-2008 prominence is almost entirely driven by the exercise-mimetic claim and its WADA-prohibited status.[1][2] No registered human trial has tested AICAR for chronic exercise-mimetic use or healthspan extension, and the human pharmacokinetics published from the cardiology era show very short plasma half-life requiring continuous infusion.[5]
Regulatory: Not FDA-approved. Investigated historically as acadesine for cardioprotection and CLL (discontinued). On the WADA Prohibited List (S4 hormone and metabolic modulators) since 2009. Research-grade material for non-clinical use; no chronic-use human safety data exists.
AICAR: Mechanisms, Half-Life & Research Data
A skimmable deep dive into how AICAR works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.
How it works
AICAR is the nucleoside form of an endogenous intermediate (ZMP, the monophosphorylated form) in the de-novo purine-biosynthesis pathway. Exogenous AICAR is taken up by cells via adenosine transporters and phosphorylated to ZMP by adenosine kinase. ZMP mimics AMP and allosterically activates AMPK — the conserved master cellular energy sensor that responds to a falling ATP:AMP ratio by switching cells from anabolic toward catabolic metabolism.[3][6] Activated AMPK phosphorylates a wide downstream set of targets: it inhibits acetyl-CoA carboxylase (deinhibiting fatty-acid β-oxidation), inhibits mTORC1 (suppressing protein synthesis and anabolic growth), stimulates GLUT4 translocation (increasing glucose uptake into skeletal muscle), and via CREB and PGC-1α drives mitochondrial biogenesis.[6] In skeletal muscle, the Narkar 2008 Cell paper reported that 4 weeks of AICAR injection in sedentary mice was sufficient to reprogram fibre type toward oxidative and to substantially increase running endurance — without exercise — leading to the "exercise mimetic" framing that drove most subsequent attention.[1] Human pharmacokinetic data from the historic acadesine cardioprotection program show very short plasma half-life and require continuous intravenous infusion for sustained exposure — a fact that complicates any "supplement"-style oral or bolus subcutaneous use.[5]
Active research areas
- Exercise-mimetic phenotype (pre-clinical foundational)The Narkar 2008 Cell paper remains the foundational result: 4 weeks of intraperitoneal AICAR substantially increased running endurance in sedentary mice and reprogrammed muscle-fibre composition.[1] The result has been replicated in skeletal-muscle culture but no comparable human exercise-endurance study has been conducted.
- Acadesine cardioprotection (discontinued)AICAR was developed historically as acadesine for ischemia–reperfusion cardioprotection during cardiac surgery; published Phase 3 work showed mixed results and the program did not advance to approval.[5]
- Acadesine in chronic lymphocytic leukemia (discontinued)A multicentre Phase I/II study evaluated acadesine in relapsed/refractory CLL. The program did not advance to Phase 3 approval.[4]
- Doping pharmacology (real-world dominant use case)AICAR is on the WADA Prohibited List in Section S4.4 (Metabolic Modulators) and any athlete subject to in-competition anti-doping testing should not use it.[2]
Open questions & leading hypotheses (1)
- Hypothesis: The mouse exercise-mimetic phenotype of AICAR will translate to humans at safe chronic doses, providing a real "exercise without exercise" benefit.Evidence: The Narkar mouse result is striking and the AMPK mechanism is conserved across mammals; AMPK activation is the same downstream pathway recruited by metformin and by physical exercise.[1][3][6] Counter-evidence: no human exercise-endurance trial of AICAR has been conducted, despite the Narkar paper being nearly two decades old — a long gap that suggests development barriers; the published human pharmacokinetics show very short plasma half-life requiring continuous infusion, which is incompatible with any practical chronic-supplement use;[5] mice and humans have very different muscle-fibre composition and energetics, and translation of fibre-type-reprogramming effects from sedentary mice to active humans is not established; AICAR's WADA-prohibited status and the cardiology-era development failures both suggest that the chronic-use safety case is not strong enough to support the supplement-style use the molecule attracts.
What community users report
Anecdotal — not controlled-trial evidence
On r/Peptides and r/PEDs, AICAR is discussed as an "exercise-mimetic" research peptide alongside SR-9009 and GW-501516, with typical subcutaneous protocols of 30–60 mg several times per week on a short cycle.[8] Users report subjective improvements in endurance and recovery; many threads acknowledge the very short plasma half-life and frame the practical effect as modest. **These reports are anecdotal and have not been validated in human controlled trials; the consumer-dose schedule is extrapolated from mouse studies and is largely incompatible with the short human plasma half-life;[5] AICAR is WADA-prohibited and any athlete subject to in-competition anti-doping testing should not use it;[2] AICAR is not FDA-approved for any indication.**
Sources & references (8)
Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.
- [1]Narkar VA et al. AMPK and PPARδ agonists are exercise mimetics. Cell 2008;134:405–415. · PMID: 18674809 link
- [2]World Anti-Doping Agency Prohibited List — Section S4.4 (Metabolic Modulators) includes AICAR. link
- [3]Corton JM et al. 5-Aminoimidazole-4-carboxamide ribonucleoside: a specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 1995;229:558–565. · PMID: 7744080 link
- [4]Van den Neste E et al. Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicentre phase I/II study. Cancer Chemother Pharmacol 2013;71:581–591. · PMID: 23228992 link
- [5]Dixon R et al. Clinical pharmacokinetics and tolerability of acadesine in normal volunteers and patients undergoing CABG surgery. J Clin Pharmacol 1991;31:342–347 — pharmacokinetic profile of intravenous AICAR. · PMID: 2037708 link
- [6]Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012;13:251–262 — review of AMPK pharmacology. · PMID: 22436748 link
- [7]Drake JC et al. AMP-activated protein kinase and the regulation of autophagic proteolysis. J Biol Chem 2014 — context for AMPK / mitophagy mechanism downstream of AICAR. · PMID: 24385428 link
- [8]Community report — r/Peptides and r/PEDs AICAR discussion threads (subreddits), accessed May 2026. link
AICAR Calculator Input Observations
In lifetime AICAR calculator inputs, 1mg is the most frequent entered amount (11 of 39 runs). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length.
About AICAR
AICAR is a small-molecule AMPK activator (a nucleotide analogue) studied in metabolic and exercise-physiology research. It is a chemical compound, not a peptide, so the certificate of analysis (COA) is about chemical purity and identity rather than a sequence.
AICAR is tracked under the Performance Peptides category on WPA. Its reported half-life is ~1 hour. Calculator inputs do not establish why a cadence was selected or validate a protocol. Not FDA-approved.
Frequently Asked Questions: AICAR
Are current AICAR offers available?
Current AICAR vial offers are unavailable in this comparison. Research information remains available; this does not establish permanent discontinuation.
What can I check if AICAR listings become available?
Check the exact compound, format, labelled quantity, named laboratory, test date, and batch match. Confirm any future listing price, discount terms, and stock directly with the vendor. Catalog COA fields alone are not independent verification.
Does research activity establish current AICAR availability?
No. Search interest, calculator entries, historical prices, related compounds, and other formats do not establish current offers in this comparison. Research information and navigation to other compounds remain available.